Compagnie Du Mont-Blanc (MLCMB)
Euronext Paris · France · prices in EUR · close of 22 Oct 2026
Key indicators
| Last close | EUR 250.00 |
|---|---|
| 52-week range | 218.00 – 312.00 |
| Return, 1 month / 3 months | −0.8% / +3.3% |
| Return, 1 year / 3 years | +4.6% / +121.5% |
| Trend | Below its 200-day average |
| RSI (14) | 44 |
| Volatility (1 year) | 28.1% |
| Worst drawdown (1 year) | -29.7% |
| Average daily value traded | 0.01M EUR |
| Dividend yield | 3.4% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Compagnie du Mont-Blanc operates the mountain transport that carries visitors around the Chamonix valley in the French Alps. Its cable cars, lifts and mountain railways take tourists and skiers up to high viewpoints, glaciers and ski areas, including the celebrated ascent toward the Aiguille du Midi and the rack railway to the Mer de Glace. The company is based in Chamonix and serves leisure travellers, skiers and mountaineers who come to the Mont-Blanc region throughout the year.
The shares are listed on the Euronext Paris in France under the code MLCMB, and the price on this page is in euros (EUR). Our dividend records, which start in 2019, show payments in 6 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Compagnie Du Mont-Blanc (MLCMB) trades on the Euronext Paris in France. It last closed at EUR 250.00 on 22 October 2026.
Its price-based Market X-Ray is 59 out of 100 (a fair price profile), ranking 233 of 625 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 4.6% and over the last three months it rose 3.3%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Euronext Paris
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 69 · Fair | Mixed trend against its averages. | |
| Above 200-day average | -0.7% | ||
| From 52-week high | -19.4% | ||
| Momentum | 70 · Fair | Typical recent returns for this exchange. | |
| 3-month return | 3.3% | ||
| 6-month return | -2.3% | ||
| 12-month return, skipping the last month | 5.4% | ||
| Stability (higher is calmer) | 67 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 28.1% | ||
| Worst drawdown, 1 year (smaller is calmer) | -29.7% | ||
| Liquidity | 33 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.01M EUR | ||
| Zero-volume days | 3.3% | ||
| Income | 29 · Weak | Dividend is small or irregular. | |
| Dividend yield | 3.4% | ||
| Years with dividends | 4 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Liquidity: Thinly traded: prices can jump and exits can be hard.
- Income: Dividend is small or irregular.
Returns
| 1 week | −0.8% |
|---|---|
| 1 month | −0.8% |
| 3 months | +3.3% |
| 6 months | −2.3% |
| 1 year | +4.6% |
| 3 years | +121.5% |
| 5 years | +133.9% |
Signals
| 50-day / 200-day average | 253.00 / 251.77 |
|---|---|
| Golden / death cross (60 days) | Golden, 6 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 1.91 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 10 Dec 2025 | EUR 8.5000 |
| 11 Dec 2024 | EUR 8.0000 |
| 6 Dec 2023 | EUR 6.5000 |
| 7 Dec 2022 | EUR 5.0000 |
| 2 Dec 2020 | EUR 3.2000 |
| 4 Dec 2019 | EUR 4.0000 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Euronext Paris; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.